Clarus Group Inc. Sells 111 Shares of Chemed Co. (NYSE:CHE)

Clarus Group Inc. trimmed its stake in Chemed Co. (NYSE:CHE) by 7.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,395 shares of the company’s stock after selling 111 shares during the period. Clarus Group Inc.’s holdings in Chemed were worth $739,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. EP Wealth Advisors LLC raised its stake in shares of Chemed by 1.9% in the 3rd quarter. EP Wealth Advisors LLC now owns 1,354 shares of the company’s stock valued at $814,000 after acquiring an additional 25 shares in the last quarter. Ballentine Partners LLC raised its stake in shares of Chemed by 4.1% in the 3rd quarter. Ballentine Partners LLC now owns 655 shares of the company’s stock valued at $394,000 after acquiring an additional 26 shares in the last quarter. First Heartland Consultants Inc. raised its stake in shares of Chemed by 7.2% in the 3rd quarter. First Heartland Consultants Inc. now owns 508 shares of the company’s stock valued at $305,000 after acquiring an additional 34 shares in the last quarter. First Trust Direct Indexing L.P. raised its stake in shares of Chemed by 4.5% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 887 shares of the company’s stock valued at $533,000 after acquiring an additional 38 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of Chemed by 11.5% in the 3rd quarter. KBC Group NV now owns 378 shares of the company’s stock valued at $227,000 after acquiring an additional 39 shares in the last quarter. 95.85% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $572.77, for a total transaction of $1,145,540.00. Following the sale, the chief executive officer now owns 101,735 shares of the company’s stock, valued at approximately $58,270,755.95. This trade represents a 1.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Brian C. Judkins acquired 145 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were purchased at an average cost of $519.50 per share, for a total transaction of $75,327.50. Following the acquisition, the vice president now directly owns 1,678 shares in the company, valued at $871,721. This represents a 9.46 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.32% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on CHE. StockNews.com raised Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, November 30th. Royal Bank of Canada dropped their price target on Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th.

Chemed Stock Up 0.6 %

Shares of NYSE CHE opened at $553.44 on Tuesday. The business’s 50 day moving average is $542.91 and its two-hundred day moving average is $564.81. The company has a market cap of $8.33 billion, a P/E ratio of 27.97, a P/E/G ratio of 2.16 and a beta of 0.48. Chemed Co. has a 12 month low of $512.12 and a 12 month high of $654.62.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.